Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.43 |
| ▸ | SELE | P16581 | 1/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.42 |
| ▸ | RARB | P10826 | 5/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.40 |
| ▸ | RELA | Q04206 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | THRA | P10827 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30827012 | 0.90 | CYP11B1 (0.47) | CYP11B1CYP11B2 | |
| SCHEMBL2516239 | 0.85 | RARB (0.53) | TDP1L3MBTL1RARBALDH1A1NPC1 | |
| SCHEMBL2566879 | 0.84 | RARB (0.55) | RARBALDH1A1NPC1NFKB1RAB9A | |
| SCHEMBL2513768 | 0.84 | GPR84 (0.44) | GPR84TDP1L3MBTL1TRPV1RARB | |
| SCHEMBL31046827 | 0.81 | SMYD3 (0.52) | L3MBTL1CYP11B1CYP11B2SMN1; SMN2 | |
| SCHEMBL9607829 | 0.81 | SMYD3 (0.52) | L3MBTL1CYP11B1CYP11B2SMN1; SMN2 | |
| SCHEMBL28111983 | 0.80 | RARB (0.51) | TDP1L3MBTL1RARBCYP3A4ALDH1A1 | |
| Hydrochloric Acid SCHEMBL29793528 | 0.80 | SMYD3 (0.51) | L3MBTL1CYP11B1CYP11B2SMN1; SMN2 | |
| SCHEMBL27733869 | 0.78 | TDP1 (0.59) | GPR84TDP1L3MBTL1CYP3A4PTGS2 | |
| SCHEMBL1758170 | 0.78 | MKNK1 (0.57) | CYP11B1CYP11B2RARBALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113527195-A | 5-aryl nicotinamide LSD1/HDAC double-target inhibitor, preparation method and application thereof | 新乡医学院 | 2021-10-22 | — | — | CN | claimed |
| EP-1569907-B1 | NICOTINAMIDE-BASED KINASE INHIBITORS | YM BIOSCIENCES AUSTRALIA PTY (AU) | 2016-03-09 | — | — | EP | disclosed |
| US-8030336-B2 | Nicotinamide-based kinase inhibitors | YM BIOSCIENCES AUSTRALIA PTY LTD (AU) | 2011-10-04 | — | — | US | disclosed |
| EP-1569907-A4 | NICOTINAMIDE-BASED KINASE INHIBITORS | CYTOPIA PTY LTD (AU) | 2007-10-31 | — | — | EP | disclosed |
| US-20070060619-A1 | Nicotinamide-based kinase inhibitors | CYTOPIA PTY LTD (AU) | 2007-03-15 | — | — | US | disclosed |
| EP-1569907-A1 | NICOTINAMIDE-BASED KINASE INHIBITORS | Cytopia PTY Ltd (AU) | 2005-09-07 | — | — | EP | disclosed |
| WO-2004054977-A1 | NICOTINAMIDE-BASED KINASE INHIBITORS | CYTOPIA PTY LTD (AU) | 2004-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060619-A1 | Nicotinamide-based kinase inhibitors | NADK, NAMPT, PDXK | GPR84 1877/4885TDP1 1139/4885L3MBTL1 3769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.